The biopharma division of IGL reported net revenue of Rs 246 crore, EBITDA of Rs 29 crore and a gross margin of 40.1% in FY26 ...

Its Rs 280 crore capital expenditure programme remains on track for completion by FY27, with Rs 160 crore already deployed ...

The company's consolidated total revenue from operations for the July–September quarter fell 29.8% to Rs. 4,247.32 crore ...

Operating performance also strengthened significantly, with consolidated EBITDA climbing 55% year-on-year to Rs 36.52 crore ...

The recommendation was made after the World Health Organization's Technical Advisory Group on Candidate Vaccine Prioritization (TAG-CVP) reviewed the available evidence ...

Novo Nordisk has raised its full-year 2026 outlook for adjusted sales and operating profit following a stronger-than-expected ...

Alembic Pharmaceuticals Limited reported a massive 81% year-on-year surge in consolidated profit after tax (PAT) to Rs. 335 ...

Sevabertinib is an oral, reversible, small-molecule tyrosine kinase inhibitor (TKI) designed to target HER2-activating ...

Pharma major Lupin has delivered double-digit revenue growth in the September quarter, but a sharp rise in expenses weighed ...

Aurobindo Pharma has posted its highest-ever quarterly revenue of Rs 10,263 crore for the second quarter of FY27, registering ...

The expanded collaboration combines DifGen’s development and US manufacturing capabilities with Alembic’s established US ...

Biocon Limited reported consolidated operating revenue of Rs 4,389 crore for the second quarter of FY27, up 2% year-on-year ...